Brief: Quantum Genomics Signs Exclusive License And Production Deal With Julphar
Dec 6 (Reuters) - QUANTUM GENOMICS SA ALQGC.PA :
* SIGNS EXCLUSIVE LICENSE AND PRODUCTION AGREEMENT WITH
JULPHAR TO
MARKET AND PRODUCE FIRIBASTAT IN MIDDLE EAST, AFRICA, CIS AND
TURKEY
* WILL RECEIVE UP TO $20 M IN UPFRONT, DEVELOPMENT AND SALES
MILESTONE PAYMENTS AS WELL AS ROYALTIES ON FUTURE SALES
* JULPHAR HAS ALSO PLEDGED TO INVEST $2 M IN QUANTUM
GENOMICS
THROUGH A PRIVATE PLACEMENT, DETAILS TO BE ANNOUNCED SHORTLY
Source text for Eikon: urn:newsml:reuters.com:*:nACT72207
Further company coverage: ALQGC.PA JULPHAR.AD
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study